Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Research and Development of New Drugs	53.53M	155.71M	63.52M	95.75M	152.81M
Research and Development of New Drugs Growth	-65.62%	145.13%	-33.66%	-37.34%	-68.58%
Total	53.53M	155.71M	63.52M	95.75M	152.81M
Total Growth	-65.62%	145.13%	-33.66%	-37.34%	-68.58%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
The People's Republic of China (The PRC)	53.53M	155.71M	63.52M	95.75M	152.81M
The People's Republic of China (The PRC) Growth	-65.62%	145.13%	-33.66%	-37.34%	-68.58%
Total	53.53M	155.71M	63.52M	95.75M	152.81M
Total Growth	-65.62%	145.13%	-33.66%	-37.34%	-68.58%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 13, 2026

Data Sources Report a data error